Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study.
Claudia AltamuraSabina CevoliCinzia AuriliaGabriella EgeoLuisa FofiPaola TorelliNicoletta BrunelliGiulia PierangeliValentina FavoniAdriana FallacaraUmberto PensatoPiero BarbantiFabrizio VernieriPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2020)
Our study observed that the lockdown impact to 57.8 ± 8.8, p = .009), while MPI resulted unchanged (from 11.6 ± 11.5 to 11.1 ± 11.7; p = .114). MMDs, MPI, and HIT-6 variations from T-free to T-lock did not differ according to work settings or household. Patients beyond the first 3 months of therapy presented less often a reduction in MMDs (p = .006) and on everyday life did not affect the migraine load in patients receiving monoclonal antibodies inhibiting the CGRP pathway. Patients in the first months of therapy experienced a greater improvement according to drug pharmacokinetics, while women more frequently needed rescue medications, possibly indicating presenteeism or cephalalgophobia.